

Supporting Information




Figure S1. FTIR transmission spectra of (a) amine-functionalized **NaGdF₄** and **BaGdF₅** (UCNPs-PEI), (b) click reaction-modified **NaGdF₄** and **BaGdF₅** (UCNPs-ene) and (c) Plk1-specific peptides-coated **NaGdF₄** and **BaGdF₅** (UCNPs-P_n).




Figure S2. SAED patterns of NaGdF₄-P_n and BaGdF₅-P_n.




Figure S3. *In vitro* images and upconversion emission spectra in aqueous medium and *in vitro* of (a) NaGdF₄-P_n and (b) BaGdF₅-P_n.




Figure S4. Flow cytometric analysis of cell cycle interruption of HeLa under the treatment of **NaGdF₄-P_n** or **BaGdF₅-P_n**.




Figure S5. Dynamic light scattering analysis of a) $\text{BaGdF}_5\text{-P}_n$ or b) $\text{NaGdF}_4\text{-P}_n$ in PBS buffer, pH= 7.4.

IC ₅₀ (μg/mL)	Cancer		Normal	
	HeLa	HK-1	MRC-5	QSG-7701
NaGdF ₄ -PEI	398	516	435	432
NaGdF ₄ -P ₁	103	223	334	401
NaGdF ₄ -P ₂	111	183	383	609
NaGdF ₄ -P ₃	95	172	400	732
BaGdF ₅ -PEI	470	474	616	435
BaGdF ₅ -P ₁	264	229	549	322
BaGdF ₅ -P ₂	327	141	850	334
BaGdF ₅ -P ₃	221	427	669	498

Table S1. IC₅₀ values of the as-synthesized **NaGdF₄-P_n** and **BaGdF₅-P_n** in both cancer and normal cell lines.